摘要
目的评估经动脉化疗栓塞术(TACE)联合信迪利单抗及贝伐珠单抗类似物治疗不可切除肝细胞癌(uHCC)的有效性及安全性。方法回顾性分析2021年1月至2023年12月苏州大学附属第一医院收治的64例uHCC患者的临床资料。采用TACE联合信迪利单抗及贝伐珠单抗类似物(联合组)43例,单纯信迪利单抗及贝伐珠单抗类似物(对照组)21例。Kaplan-Meier法绘制生存曲线,比较两组的中位总生存期(mOS)、中位无进展生存期(mPFS)。根据mRECIST标准进行疗效评估,比较两组的客观缓解率(ORR)、疾病控制率(DCR)。观察两组患者的不良反应发生情况。结果联合组的mOS和mPFS分别为22.3个月和12.4个月,对照组分别为11.6个月和6.4个月,差异均有统计学意义(P=0.001和P=0.002)。联合组的ORR和DCR分别为62.8%和95.3%,均显著高于对照组19.0%和57.1%(均P<0.01)。两组严重不良事件的发生差异无统计学意义(P=0.518)。结论与单纯信迪利单抗及贝伐珠单抗类似物治疗相比,TACE联合信迪利单抗及贝伐珠单抗类似物治疗uHCC具有良好的有效性和安全性。
ObjectiveTo investigate the efficacy and safety of transarterial chemoembolization(TACE)combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular careinoma(uHCC).MethodsThe clinical data of 64 patients with unresectable HCC,who were admitted to the First Affiliated Hospital of Soochow University between January 2021 and December 2023,were retrospectively analyzed.The patients were divided into a combination group(n=43,receiving TACE combined with sintilimab and bevacizumab biosimilar)and control group(n=21,receiving only sintilimab and bevacizumab biosimilar).Survival curves were drawn by Kaplan-Meier method,and the median overall survival(mOS)and median progression-free survival(mPFS)were compared between the two groups.According to the mRECIST criterion,the objective response rate(ORR)and disease control rate(DCR)were compared between the two groups.The occurrences of adverse events in both groups were recorded.ResultsThe mOS and mPFS in the combination group were 22.3 months and 12.4 months,respectively,which in the control group was 11.6 months and 6.4 months,respectively.The differences between the two groups were statistically significant(P=0.001 and P=0.002).The ORR and DCR in the combination group were 62.8%and 95.3%respectively,which were significantly higher than 19.0%and 57.1%respectively in the control group(all P<0.01).No statistically significant difference in the incidence of severe adverse events existed between the two groups(P=0.518).ConclusionTACE combined with sintilimab and bevacizumab biosimilar has efficacy and safety than sintilimab and bevacizumab biosimilar alone.
作者
杨浩
黄金涛
胡笛
仲斌演
沈健
朱晓黎
Yang Hao;Huang Jintao;Hu Di;Zhong Binyan;Shen Jian;Zhu Xiaoli(Department of Interventional Radiology,the First Affiliated Hospital of Soochow University,Suzhou 215000,China)
出处
《中华内科杂志》
北大核心
2025年第2期134-141,共8页
Chinese Journal of Internal Medicine
基金
江苏省自然科学基金面上项目(SBK2023022210)
苏州大学临床创新交叉转化项目(ML12203323)
苏大附一院博习临床研究项目(BXLC010)。
关键词
癌
肝细胞
化学栓塞
治疗性
抗肿瘤联合化疗方案
Carcinoma,hepatocellular
Chemoembolization,therapeutic
Antineoplastic combined chemotherapy protocols
作者简介
通信作者:朱晓黎,Email:zhuxiaoli90@163.com。
